Mucopolysaccharidosis type II--genotype/phenotype aspects.

Area of Science:

• Biochemistry
• Genetics
• Rare Diseases

Background:

• Mucopolysaccharidosis type II (MPS II), or Hunter disease, exhibits significant clinical heterogeneity.
• Current enzyme activity assays for iduronate-2-sulphatase (IDS) in MPS II lack the sensitivity to distinguish between absent and residual enzyme function.
• This limitation hinders accurate prediction of disease severity and prognosis.

Purpose of the Study:

• To explore the challenges and benefits of establishing genotype-phenotype correlations in lysosomal storage diseases, using MPS II as a model.
• To investigate the relationship between genetic mutations and clinical presentation in MPS II patients.
• To assess the utility of genotype information in guiding treatment decisions for MPS II.

Main Methods:

• Analysis of genotype-phenotype relationships in MPS II patients.
• Evaluation of iduronate-2-sulphatase (IDS) enzyme activity.
• Assessment of patient responses to allogenic bone marrow transplantation.

Main Results:

• Genotype-phenotype correlations in MPS II are complex and not always predictable based on residual enzyme activity.
• Gene analysis, expression, and transcript studies do not consistently predict a patient's clinical phenotype.
• Variability in bone marrow transplant outcomes highlights the influence of specific genotypes.

Conclusions:

• Establishing definitive genotype-phenotype correlations in MPS II is difficult due to limitations in measuring enzyme activity.
• The variable response to bone marrow transplantation underscores the importance of genetic profiling for personalized MPS II therapy selection.